Mineralys Drug Cuts Kidney Damage Marker 52% in Trial
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat reduced a key marker of kidney damage by 52.2% compared with placebo in patients with …
Mineralys Drug Cuts Kidney Damage Marker 52% in Trial Read More